APA (7th ed.) Citation

CS, F., K, S., S, K., E, W., A, G., M, K., . . . JE, N. (2025). Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol. Research square. https://doi.org/10.21203/rs.3.rs-6666196/v1

Chicago Style (17th ed.) Citation

CS, Freet, et al. "Efficacy of the GLP-1 Receptor Agonist, Semaglutide, in Abstinence from Illicit and Nonprescribed Opioids in an Outpatient Population with Treatment-refractory OUD: A Randomized, Double-blind, Placebo-controlled Clinical Trial Protocol." Research Square 2025. https://doi.org/10.21203/rs.3.rs-6666196/v1.

MLA (9th ed.) Citation

CS, Freet, et al. "Efficacy of the GLP-1 Receptor Agonist, Semaglutide, in Abstinence from Illicit and Nonprescribed Opioids in an Outpatient Population with Treatment-refractory OUD: A Randomized, Double-blind, Placebo-controlled Clinical Trial Protocol." Research Square, 2025, https://doi.org/10.21203/rs.3.rs-6666196/v1.